Syncona led the 80 million euros ($85.7 million) series B financing for Netherlands=based iOnctura which is focused on lead asset roginolisib, described as the first allosteric modulator of PI3Kδ.
The other cancer-focused biotech that Syncona has parked in its portfolio is Yellowstone, a U.K.-based company targeting human leukocyte antigen (HLA) class II expression in a range of common cancers. Syncona has given the preclinical company, which spun out of the University of Oxford, £16.5 million ($20.9 million) in series A funds to build up its pipeline. Source: Fierce Biotech 20/6/2024